2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
04:30 p.m. - 06:00 p.m.
MCCNO - Hall C
This session are outstanding clinical trials in ET and PV. Suggested session title<br /><br /><span style="caret-color: #000000; color: #000000; font-family: Aptos, Aptos_EmbeddedFont, Aptos_MSFontService, Calibri, Helvetica, sans-serif; font-size: 14.666667px; font-style: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration: none; display: inline !important; float: none;">ET and PV: Moving Beyond Conventional Therapy</span>
Treatment Considerations, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Adverse Events, Biological Processes, Genomics, Hematopoiesis, Immune Mechanism, Clinical Practice (Health Services and Quality), Diseases, Bleeding and Clotting, Bleeding Disorders, Platelet Disorders, Thromboembolism, Thrombotic Disorders, VWD, Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Translational Research, MDS, MPN, CMML, Clinical Research, Clinical Trials, Study Population, Human, Adult, Elderly, Young Adult
PAPER

1033 First data from Phase 1 study of safety and efficacy of JNJ-88549968, a mutant calreticulin (CALRmut) x CD3 T-cell engaging antibody for the treatment of essential thrombocythemia (ET)

Naveen Pemmaraju, MD, Florian Heidel2, Vincent Alcazer, MD PhD3, Mathew G. Angelos, MD, PhD4, Hugues de Lavallade5, Joachim Goethert, MD6, Michael R. Grunwald, MD7, Vikas Gupta, MD FRCP, FRCPath8, Claire Harrison, DM9, Juan Carlos Hernandez Boluda, MD, PhD10, Daniel Heudobler11, Elizabeth Hexner, MD12, Anthony Michael Hunter, MD13, Marie Luise Hütter-Krönke, MD14, Susanne Isfort, MD15, Jean-Jacques Kiladjian16, Ilya Kirgner, MD17, Steffen Koschmieder, MD18, Andrew T Kuykendall, MD19, David Lavie, MD20, Philipp le Coutre, MD21, Ioannis Mantzaris, MD, MS22, Elena Mischenko23, Jenny O'Nions, MD24, Salman Otoukesh, MD25, Francesca Palandri, MD, PhD26, Francesco Passamonti, MD27, Kristen Pettit, MD28, Keith W. Pratz, MD29, Daniel Royston, DPhil, FRCPath, MBBChir30, Srinivasa Sanikommu, MD31, Tim Sauer32, Stephen A. Strickland, MD33, Blanca Xicoy, PhD34, Junichiro Yuda, MD, PhD35, Eran Zimran, MD36, Alan Aberdeen, MS37, Oliver Lomas 38, Charlotte Van Bogaert, MSc39, Nele van Slycken40, Laura Barreyro, PhD41, Rawan Rupnow42, M. Phillip Deyoung, PhD43, Arnob Banerjee44, Yu Jin Kim45, Anna Kuchnio, PhD46, Ulrike Philippar, PhD47, Nikki Daskalakis, MD48, Jessica Vermeulen, MD, PhD49, Raajit K. Rampal, MD, PhD50
1 MD Anderson Cancer Center, Houston, Texas, United States
2 Hannover Medical School, Hannover, Germany
3 Centre International de Recherche en Infectiologie, Université Claude Bernard Lyon 1, Lyon, France, Hôpital Lyon Sud, Hospices Civils de Lyon, Pierre Bénite, France
4 University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
5 Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
6 University Hospital Essen, Essen, Germany
7 Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, North Carolina, United States
8 University of Toronto, Toronto, Ontario, Canada
9 Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
10 Hospital Clínico Universitario de Valencia, Valencia, Spain
11 University Hospital Regensburg, Regensburg, Germany
12 University of Pennsylvania, Philadelphia, Pennsylvania, United States
13 Emory University, Atlanta, Georgia, United States
14 Charité – Universitätsmedizin, Berlin, Germany
15 Hannover Medical School, Hannover, Germany
16 Hôpital Saint-Louis & Université Paris Cité, Paris, France
17 Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
18 University Medical Center RWTH Aachen, Aachen, Germany
19 Moffitt Cancer Center, Tampa, Florida, United States
20 Hadassah Medical Center, Jerusalem, Israel
21 Charité – Universitätsmedizin, Berlin, Germany
22 Montefiore Einstein Cancer Center, New York City, New York, United States
23 Carmel Medical Center, Haifa, Israel
24 University College London Hospitals, London, United Kingdom
25 City of Hope National Medical Center, Duarte, California, United States
26 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
27 University of Milan, Milan, Italy
28 University of Michigan, Ann Arbor, Michigan, United States
29 University of Pennsylvania, Philadelphia, Pennsylvania, United States
30 University of Oxford, Oxford, United Kingdom
31 Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, North Carolina, United States
32 Heidelberg University Hospital, Heidelberg, Germany
33 SCRI at TriStar Centennial, Nashville, Tennessee, United States
34 Universitat Autònoma de Barcelona, Barcelona, Spain
35 National Cancer Center Hospital East, Kashiwa, Japan
36 Hadassah Medical Organization and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel
37 Ground Truth Labs, London, United Kingdom
38 Johnson & Johnson, High Wycombe, United Kingdom
39 Johnson & Johnson, Beerse, Belgium
40 Johnson & Johnson, Beerse, Belgium
41 Johnson & Johnson, Spring House, Pennsylvania, United States
42 Johnson & Johnson, Spring House, Pennsylvania, United States
43 Johnson & Johnson, Spring House, Pennsylvania, United States
44 Johnson & Johnson, Spring House, Pennsylvania, United States
45 Johnson & Johnson, Spring House, Pennsylvania, United States
46 Johnson & Johnson, Beerse, Belgium
47 Johnson & Johnson, Beerse, Belgium
48 Johnson & Johnson, Spring House, Pennsylvania, United States
49 Johnson & Johnson, Leiden, Netherlands
50 Memorial Sloan Kettering Cancer Center, New York City, New York, United States

Background

Calreticulin mutations (CALRmut) drive 30% of cases of essential thrombocythemia (ET). Compared with JAK2-mutated, patients (pts) with CALR-mutated ET tend to be younger, have more severe thrombocythemia and exhibit a higher risk of fibrotic progression. Current therapies (tx) do not consistently reduce disease burden, provide long-term platelet (PLT) control or prevent progression. JNJ-88549968 (JNJ-9968), a first-in-class CALRmutxCD3 T-cell engaging antibody, targets CALRmut to induce T-cell-mediated cytotoxicity to eradicate the CALRmut driver clone and substantially modify the course of disease. The study aims to assess safety and preliminary efficacy of JNJ-9968 in pts with CALRmut ET refractory/resistant/intolerant (R/R/I) to hydroxyurea (HU).

Methods

Primary objectives are to characterize safety and determine the RP2D. Pts received subcutaneous JNJ-9968 every 3 weeks (W) via a step-up regimen per protocol. HU was permitted; other txs were discontinued. Adverse events (AEs) were graded per CTCAE 5.0, except for CRS and ICANS, which were graded per ASTCT criteria. Complete PLT response (CR) was defined as ≤400x109/L and partial PLT response (PR) as ≤600x109/L, with durability defined as ≥12W with at least 20W since first dose. Variant allele frequency (VAF) of CALR in whole blood was analyzed centrally at baseline (BL), W6, W12 and W24 by next-generation sequencing with 10-4 sensitivity. Molecular responses were defined as best overall reduction from BL, 50–99% (partial molecular response; PMR), and 100% (complete molecular response; CMR). Changes from BL in bone marrow (BM) CALRmut IHC were assessed at W12, W24 and W48 by blinded central pathology review.

Results

As of June 5 2026, 49 pts were enrolled with median 6.0 months (range, 0-18.9) duration of study treatment. Median age was 60 yrs (range, 36–86), 27 (55%) were female, and median time since diagnosis was 6.9 yrs (range, 0.4–21.4). Twenty-two pts (45%) had received ≥3 prior lines of tx. Prior tx after HU included anagrelide 26 pts (53%) and interferon 17 pts (35%). At BL median PLT count was 520 x109/L (range, 159–1951), neutrophil count 2.94 ×10?/L (range, 0.82–12.02), Hb 12.3 g/dL (range, 8.6–15.5), with 41% pts receiving HU on Day 1 of study treatment. Among 42 pts with centrally reported data, CALRmut was 40% Type 1/1-like, 55% Type 2/2-like and 5% other.

Tx-emergent AEs (TEAEs) were seen in 90% of pts, including 49% with Grade (Gr) ≥3. Two Dose Limiting Toxicities (DLTs) were reported of thrombocytopenia/UTI and neutropenia/stomatitis in context of recent HU. No pts discontinued study drug for related TEAEs. Hematologic TEAEs: neutropenia (31% any Gr, 29% Gr ≥3), anemia (25% any Gr, 8% Gr ≥3) and thrombocytopenia (16% any Gr, 8% Gr ≥3) – nil serious. Non-hematologic TEAEs ≥20% (any Gr): injection-site reaction (69%), rash (41%), fatigue (31%), nausea, arthralgia, headache (22%), ALT increase (20%); all Gr 1–2 except 2 transient Gr 3 ALT increases. Infections were reported in 38% any Gr; 4% Gr 3. CRS occurred in 21 (43% any Gr; 37% Gr 1, 6% Gr 2, No Gr ≥3) pts. No ICANS.

31 pts met criteria for durability of platelet response - durable CR or PR in 18 pts (58%). Durable CR was observed in 13 (42%), all of which free of HU. Median duration of CR 241 days (range, 106-563) with median time to start of durable CR 17 days (range, 2-126).

From 34 pts with longitudinal molecular data, 13 achieved a response of ≥PMR, including 2 CMR; 12 achieved durable platelet CR and 1 PR. In this ≥PMR group, median reduction CALRmut VAF was 99% (range, 80-100%) across CALR mutation types (6 Type1/like; 5 Type2/like; 2 Other). Of 13 pts with PMR, 12 had longitudinal BM biopsies. Central pathology review reported undetectable CALRmut positive cells within 48W in 67% pts, with normalized megakaryocyte (Mgk) number (50%), Mgk morphology (33%) or resolved Mgk clustering (58%).

Conclusion

In pts with heavily pre-treated CALRmut ET, JNJ-9968, a CALRmutxCD3 T-cell engaging antibody, demonstrated a manageable safety profile with predominantly low grade, transient TEAEs and no discontinuations related to study drug. Across all CALRmut subtypes studied, deep molecular responses correlated with rapid and durable normalization of blood counts accompanied by profound modification of histopathologic characteristics of disease. These data support further development of JNJ-9968 and lay the foundation for disease-modifying and potentially curative tx for CALRmut ET.

Naveen Pemmaraju, MD: HemOnc Times/Oncology Times - Other (including travel support); Physician’s Education Resource - Honoraria; MDEducation - Honoraria; PVEK - Honoraria; Indy Hematology Education - Honoraria; Synapse Medical Communications - Honoraria; Takeda - Research Funding; Johnson & Johnson - Research Funding; US Department of Defense - Research Funding; AbbVie - Research Funding; Institutional funding from US Department of Defense - Research Funding; Meiji - Research Funding; Opna bio LLC - Research Funding; National Institutes of Health/National Cancer Institute (NIH/NCI) - Research Funding; Karyopharm Therapeutics - Research Funding; Sager Strong Foundation - Research Funding; Incyte - Research Funding; Menarini-Stemline Therapeutics - Research Funding; Disc Medicine - Research Funding; Karger Publishers - Patents & Royalties; ASH Committee on Communications - Consultancy (Includes expert testimony); Disc Medicine - Consultancy (Includes expert testimony); Dava Oncology - Consultancy (Includes expert testimony); Karyopharm Therapeutics - Consultancy (Includes expert testimony); Menarini-Stemline Therapeutics - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Patient Power - Consultancy (Includes expert testimony); Harborside Press - Consultancy (Includes expert testimony); Meiji - Consultancy (Includes expert testimony); Eli Lilly & Co - Consultancy (Includes expert testimony); Bristol-Myers Squibb - Consultancy (Includes expert testimony); Aptitude Health - Consultancy (Includes expert testimony); HemOnc Times/Oncology Times - Consultancy (Includes expert testimony); Celgene - Consultancy (Includes expert testimony); Aplastic Anemia and MDS International Federation - Consultancy (Includes expert testimony); Medscape - Consultancy (Includes expert testimony); CTI BioPharma Corporation - Consultancy (Includes expert testimony); MorphoSys - Consultancy (Includes expert testimony); Johnson & Johnson - Consultancy (Includes expert testimony); Menarini Group - Consultancy (Includes expert testimony); Paylex - Consultancy (Includes expert testimony); EUSA Pharma - Consultancy (Includes expert testimony); Silence Therapeutics - Consultancy (Includes expert testimony); Cimeio Therapeutics - Consultancy (Includes expert testimony); Clearview Healthcare Partners - Consultancy (Includes expert testimony); Cogent Biosciences - Consultancy (Includes expert testimony); Blueprint Medicines - Consultancy (Includes expert testimony); PharmaEssentia - Consultancy (Includes expert testimony); OncLive - Consultancy (Includes expert testimony); Intellisphere - Consultancy (Includes expert testimony); Magdalen Medical Publishing - Consultancy (Includes expert testimony); Curio Science - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); BeONe - Consultancy (Includes expert testimony); Dan's House of Hope - Consultancy (Includes expert testimony); Immunogen - Consultancy (Includes expert testimony); Opna bio LLC - Consultancy (Includes expert testimony); Pacylex - Consultancy (Includes expert testimony); Imedex - Consultancy (Includes expert testimony); Geron - Consultancy (Includes expert testimony); Astellas Pharma - Consultancy (Includes expert testimony); Cimeio Therapeutics AG - Consultancy (Includes expert testimony); Physician’s Education Resource - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); CareDx - Consultancy (Includes expert testimony); CancerNet - Consultancy (Includes expert testimony); Neopharm - Consultancy (Includes expert testimony); ASCO Cancer.Net Editorial Board - Consultancy (Includes expert testimony); PeerView Institute for Medical Education - Consultancy (Includes expert testimony); Neopharm - Consultancy (Includes expert testimony); Cimeio Therapeutics AG - Speakers Bureau.; Paylex - Speakers Bureau.; Cimeio Therapeutics AG - Membership on a Board/Advisory Committee; Paylex - Membership on a Board/Advisory Committee; Dan’s House of Hope - Membership on a Board/Advisory Committee